Myles Wolf
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Myles Wolf
Myles Wolf was last confirmed as Board Member at Akebia Therapeutics, Inc. (AKBA) in a filing dated April 28, 2022. Akebia Therapeutics, Inc. reported in an 8-K filed June 13, 2025 that Myles Wolf was appointed Class II director, effective June 10, 2025.
“The proposal to elect two Class II directors, John P. Butler and Myles Wolf, M.D., M.M.Sc., to serve until the 2028 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal was approved as follows:”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
2020-01-01–2022-04-28
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.